证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-112 规格：2ml：0.6g（按 C18H34N2O6S 计） 药品批准文号：国药准字 H32021365 注册分类：化学药品 江苏吴中医药发展股份有限公司 关于盐酸林可霉素注射液通过仿制药一致性评价的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担个别及连带责任。 近日，江苏吴中医药发展股份有限公司（以下简称"公司"）全资子公司江 苏吴中医药集团有限公司下属分支机构江苏吴中医药集团有限公司苏州制药厂 （以下简称"苏州制药厂"）收到了国家药品监督管理局（以下简称"国家药监 局"）核准签发的关于"盐酸林可霉素注射液"（以下简称"该药品"或"本品"） 的《药品补充申请批准通知书》（通知书编号：2025B04321），该药品通过仿制药 质量和疗效一致性评价（以下简称"仿制药一致性评价"）。现将相关情况公告如 下： 一、药品基本情况 药品名称：盐酸林可霉素注射液 剂型：注射剂 二、药品的其他相关情况 上市许可持有人：江苏吴中医药集团有限公司苏州制药厂 药品生产企业：江苏吴中 ...

根据国家相关政策规定，对于通过仿制药一致性评价的药品品种，在医保支付方面予以适当支持，医疗 机构应优先采购并在临床中优先选用。同品种药品通过仿制药一致性评价的生产企业达到3家以上的， 在药品集中采购等方面不再选用未通过仿制药一致性评价的品种。公司盐酸林可霉素注射液通过仿制药 一致性评价，有利于提升该药品的市场竞争力，对该药品的市场销售产生积极影响。 智通财经APP讯，*ST苏吴(600200.SH)发布公告，近日，公司全资子公司江苏吴中医药集团有限公司下 属分支机构江苏吴中医药集团有限公司苏州制药厂(简称"苏州制药厂")收到了国家药品监督管理局核准 签发的关于"盐酸林可霉素注射液"的《药品补充申请批准通知书》(通知书编号：2025B04321)，该药品 通过仿制药质量和疗效一致性评价。 ...

*ST苏吴公告，全资子公司江苏吴中医药集团有限公司苏州制药厂收到国家药监局核准签发的盐酸林可 霉素注射液《药品补充申请批准通知书》，该药品通过仿制药质量和疗效一致性评价。盐酸林可霉素注 射液2024年全国医院总销售额约为2211.65万元，已投入研发费用约313.24万元。通过一致性评价有利于 提升该药品的市场竞争力，对公司销售产生积极影响。 ...

Group 1 - The stock of *ST Suwu (600200) closed at 0.95 yuan on September 18, 2025, with an increase of 2.15% and a turnover rate of 4.14% [1] - On September 18, 2025, the net outflow of main funds was 246.04 million yuan, accounting for 8.77% of the total transaction amount [1][3] - The company has been under investigation by the China Securities Regulatory Commission (CSRC) since February 26, 2025, for suspected violations of information disclosure [1] Group 2 - The company received an administrative penalty notice on July 13, 2025, for inflating revenue and profits through transactions with related companies, with inflated revenues reported from 2020 to 2023 totaling 49.53 million yuan, 46.85 million yuan, 43.07 million yuan, and 37.67 million yuan, respectively [1] - The inflated profits during the same period were reported as 1.46 million yuan, 2.03 million yuan, 1.99 million yuan, and 2.12 million yuan [1] - The company’s stock has been subject to a delisting risk warning since July 14, 2025, due to the potential for major illegal delisting circumstances [1][3]

Group 1 - The stock of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu) closed at 0.95 yuan on September 18, 2025, with a market capitalization of 675 million yuan, reflecting a 2.15% increase from the previous trading day [1] - The stock experienced a trading volume of 28.05 million yuan and a turnover rate of 4.14% on the same day [1] Group 2 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. issued its eleventh risk warning regarding the potential for major illegal forced delisting due to suspected violations of information disclosure [2] - The company has been under investigation by the China Securities Regulatory Commission (CSRC) since February 26, 2025, for alleged violations [2] - The company’s subsidiaries were found to have inflated revenue, costs, and profits through transactions with related companies, with inflated revenues reported from 2020 to 2023 totaling approximately 494.26 million yuan, 468.51 million yuan, 430.75 million yuan, and 376.66 million yuan, representing 26.46%, 26.39%, 21.26%, and 16.82% of the respective reported revenues [2] - The inflated total profits during the same period amounted to approximately 14.58 million yuan, 20.27 million yuan, 19.92 million yuan, and 21.22 million yuan [2] - The stock has been subject to delisting risk warnings since July 14, 2025, and if formal penalties confirm delisting criteria, the stock will be terminated from listing [2]

Core Viewpoint - Two listed companies, *ST Suwu and *ST Zitian, are facing delisting procedures due to serious financial fraud, highlighting the increasing regulatory scrutiny in the capital market [1][2]. Group 1: Delisting Procedures - *ST Suwu's stock price closed at 0.95 yuan per share, below the 1 yuan face value, risking delisting due to price [1][2]. - *ST Zitian has entered a delisting preparation period, with its stock expected to be delisted by October 13, 2025 [2]. Group 2: Financial Fraud Details - *ST Suwu inflated its revenue by a total of 4.95 billion, 4.69 billion, 4.31 billion, and 3.77 billion yuan from 2020 to 2023 [3]. - The company also had non-operational fund occupation by related parties totaling 47.56 billion yuan from the end of 2020 to the end of 2023 [3]. - *ST Zitian inflated its revenue by a total of 24.99 billion yuan over two years, with 7.78 billion yuan in 2022 alone, accounting for 44.59% of its revenue [4]. Group 3: Investor Compensation - Legal channels for investor compensation have opened, with specific periods defined for *ST Suwu and *ST Zitian for eligible claims [5]. - The increasing awareness of investor rights and the rising costs of violations for listed companies are evident in these cases [5]. - Audit firms involved in these companies may also face legal consequences for their roles in the financial fraud [5].

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-111 江苏吴中医药发展股份有限公司关于公司股票 可能被实施重大违法强制退市的第十一次风险提示公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 一、公司股票可能被实施重大违法强制退市风险暨立案调查进展情况 截至本公告披露日，公司尚未收到就上述立案调查事项的正式处罚决定，公 司将全力配合中国证监会的相关工作,并严格按照相关要求履行信息披露义务。 如根据正式的行政处罚决定书结论，公司触及重大违法强制退市情形，公司股票 将被终止上市。 二、其他说明及风险提示 1、公司将全力配合中国证监会的相关工作，最终结果以中国证监会出具的 正式处罚决定为准。敬请广大投资者关注后续公告并注意投资风险。 2、根据《上海证券交易所股票上市规则》第 9.5.7 条、第 9.5.8 条，如公 司后续收到行政处罚决定书，显示公司触及重大违法类强制退市情形，公司将申 请停牌，并及时披露有关内容。上海证券交易所将在停牌之日起的 5 个交易日内， 向公司发出拟终止股票上市的事先告 ...

Group 1 - The average stock price of A-shares is 13.49 yuan, with 24 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.51 yuan [1] - Among the low-priced stocks, 12 are ST stocks, accounting for 50% of the total [1] - The Shanghai Composite Index closed at 3831.66 points as of September 18 [1] Group 2 - Among the low-priced stocks, 11 increased in price today, with the highest gainers being Yongtai Energy (up 10.32%), Liao Port Co. (up 2.75%), and *ST Su Wu (up 2.15%) [1] - Conversely, 11 stocks decreased in price, with the largest declines seen in Rongsheng Development (down 8.54%), *ST Gao Hong (down 5.56%), and Zhitian Tui (down 5.36%) [1] - The stock price performance of low-priced stocks shows a mixed trend, indicating volatility in this segment [1]

Core Viewpoint - The ongoing dispute over the exclusive agency rights for the "AestheFill" product between Aimeike and *ST Suwu has seen new developments, with a recent arbitration decision impacting sales and distribution rights in mainland China [1][2][3]. Summary by Relevant Sections Arbitration Decision - The emergency arbitrator's decision prohibits Korean REGEN Company (Aimeike's subsidiary) from independently selling "AestheFill" in mainland China until the arbitration outcome is determined [1]. - The decision also affirms that DaTou Medical (*ST Suwu's subsidiary) remains the exclusive distributor of AestheFill in mainland China [1][3]. Company Responses - An internal source from Aimeike clarified that the recent decision is not a final arbitration result but a preliminary measure to protect rights before the final ruling [2]. - *ST Suwu stated that REGEN must cease any other sales methods in mainland China, reinforcing their position as the exclusive distributor [3]. Financial Implications - *ST Suwu highlighted that losing the AestheFill rights could significantly impact their revenue, with projected sales of 326 million yuan in 2024, accounting for 20.42% of total revenue, and a gross profit of 269 million yuan, representing 34.80% of total gross profit [16]. - The first quarter of 2025 is expected to see AestheFill sales of 113 million yuan, making up 35.55% of total revenue and 45.77% of gross profit [16]. Product Background - AestheFill, known as "童颜针" (youthful needle), is a regenerative aesthetic injection agent used for filling and improving wrinkles, with a market price ranging from 19,800 yuan to 23,700 yuan per unit [16].

Group 1 - The average stock price of A-shares is 13.65 yuan, with 24 stocks priced below 2 yuan, the lowest being *ST Gao Hong at 0.54 yuan [1] - Among the low-priced stocks, 12 are ST stocks, accounting for 50% of the total [1] - The Shanghai Composite Index closed at 3876.34 points as of September 17 [1] Group 2 - Among the low-priced stocks, three increased in price today, with *ST Yuan Cheng leading at a rise of 4.97% [1] - The majority of low-priced stocks, 17 in total, experienced declines, with Rongsheng Development falling by 6.13% [2][1] - The trading volume and turnover rates vary significantly among low-priced stocks, with *ST Gao Hong having a turnover rate of 0.24% [1]